IP Library Granted Patent US 12,201,688
Granted Patent B2
US 12,201,688 · App. 18/059,726 · Granted Jan 21, 2025

Lipidated immune response modifier compound compositions, formulations, and methods

Inventor: Paul D. Wightman (St. Paul, MN)
Assignee: Solventum Intellectual Properties Company
A61K39/39A61K9/0019A61K9/10A61K9/127A61K31/437A61K31/47A61K39/0011A61K39/145A61K47/26C07D471/04C12N7/00A61K2039/54A61K2039/55511A61K2039/55555A61K2039/55572A61K2039/572C12N2760/16134Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,201,688
App. No.
18/059,726
Granted
Jan 21, 2025
Kind
B2
Abstract

The compound N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide is a useful drug compound for enhancing immune response and can be used, for example, as a retrovirus vaccine adjuvant.

Claims (11)

1. A pharmaceutical composition comprising:

a compound of formula:

a pharmaceutically acceptable carrier; and

an antigen comprising a retrovirus vaccine.

2. The pharmaceutical composition of claim 1 , wherein the antigen comprises a lentivirus vaccine.

3. The pharmaceutical composition of claim 1 , wherein the antigen comprises a human immunodeficiency virus (HIV) vaccine.

4. A pharmaceutical composition of claim 1 further comprising liposomes.

5. The pharmaceutical composition of claim 1 , wherein the compound and antigen are admixed into a single composition.

6. The pharmaceutical composition of claim 1 , wherein the compound and antigen are present in separate components of the composition to be administered in combination.

7. A method of enhancing the effectiveness of a vaccine antigen by administering as a vaccine adjuvant the compound N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide, or a pharmaceutically acceptable salt thereof.

8. The method of claim 7 wherein the compound is incorporated into a liposome formulation.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2024
From: 3M INNOVATIVE PROPERTIES COMPANY
To: SOLVENTUM INTELLECTUAL PROPERTIES COMPANY
Reel/Frame 066438/0301 →